{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:36:27Z","timestamp":1787070987252,"version":"build-2736575974"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>The real-world intracranial efficacy data of ceritinib at a dose of 450 mg quaque die (QD) are currently unavailable. Therefore, we evaluated the intracranial efficacy of ceritinib (450 mg QD) in anaplastic lymphoma kinase (ALK)-rearrangement NSCLC patients in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>In total, 57 ALK-rearrangement NSCLC patients with brain metastases (BM) were enrolled retrospectively in this real-world study. Of these, 53 patients experienced progression at baseline during or after prior crizotinib administration, and 24 patients received prior brain radiotherapy. Patients received ceritinib (450 mg QD) treatment. Intracranial efficacy [objective response rate (ORR) and disease control rate (DCR)] was evaluated according to the Response Assessment in Neuro-Oncology (RANO) standard; progression-free survival (PFS) and adverse events (AEs) data were obtained through follow-ups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The intracranial ORR and DCR of ceritinib were 73.7% and 93.0%, respectively. The median intracranial PFS in patients reaching the endpoint was 8.75 months, whereas the median intracranial PFS in all patients was not reached and predicted to be not evaluable (NE) (95% CI: 12.9\u2013NE). The estimated 12-month event-free probability (EFP) of intracranial lesions was 68.1%. A subgroup analysis revealed that the estimated 12-month EFP of intracranial lesions was relatively higher in patients with prior brain radiotherapy (93.8% vs. 47.1%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0006).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Ceritinib administered at 450 mg QD to ALK-rearrangement NSCLC patients with BM in China exhibited superior ORR and DCR, as well as PFS and event free probability. The estimated 12-month EFP for intracranial lesions improved in patients with prior brain radiotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_1453_21","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T06:10:28Z","timestamp":1679897428000},"page":"516-524","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Clinical data from the real world"],"prefix":"10.4103","volume":"18","author":[{"given":"Zhixin","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhong","family":"Xian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunrong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-28-20241021","first-page":"45","article-title":"Chemoradiotherapy for stage III non-small cell lung cancer: Have we reached the limit?","volume":"4","author":"Xu","year":"2015","journal-title":"Chin Clin Oncol"},{"key":"R2-28-20241021","first-page":"703","article-title":"[Current Status for Anaplastic Lymphoma Kinase in Non-small Cell Lung Cancer]","volume":"21","author":"Song","year":"2018","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"R3-28-20241021","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.4103\/0973-1482.170940","article-title":"Evaluation of anaplastic lymphoma kinase expression in nonsmall cell lung cancer; A tissue microarray analysis","volume":"12","author":"Roudi","year":"2016","journal-title":"J Cancer Res Ther"},{"key":"R4-28-20241021","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N Engl J Med"},{"key":"R5-28-20241021","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"key":"R6-28-20241021","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1158\/2159-8290.CD-13-0846","article-title":"The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer","volume":"4","author":"Friboulet","year":"2014","journal-title":"Cancer Discov"},{"key":"R7-28-20241021","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S1470-2045(15)00614-2","article-title":"Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): Updated results from the multicentre, open-label, phase 1 trial","volume":"17","author":"Kim","year":"2016","journal-title":"Lancet Oncol"},{"key":"R8-28-20241021","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1200\/JCO.2015.65.5936","article-title":"Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: Results From ASCEND-2","volume":"34","author":"Crin\u00f2","year":"2016","journal-title":"J Clin Oncol"},{"key":"R9-28-20241021","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1470-2045(17)30339-X","article-title":"Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): A randomised, controlled, open-label, phase 3 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol"},{"key":"R10-28-20241021","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): A randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"key":"R11-28-20241021","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.3747\/co.20.1481","article-title":"Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases","volume":"20","author":"Ali","year":"2013","journal-title":"Curr Oncol"},{"key":"R12-28-20241021","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1200\/JCO.2005.08.026","article-title":"Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: A retrospective review by the Southwest Oncology Group","volume":"23","author":"Gaspar","year":"2005","journal-title":"J Clin Oncol"},{"key":"R13-28-20241021","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1200\/JCO.2011.38.0527","article-title":"Summary report on the graded prognostic assessment: An accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases","volume":"30","author":"Sperduto","year":"2012","journal-title":"J Clin Oncol"},{"key":"R14-28-20241021","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1158\/1078-0432.CCR-11-2906","article-title":"Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer","volume":"18","author":"Doebele","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R15-28-20241021","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1200\/JCO.2014.59.0539","article-title":"Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases","volume":"33","author":"Costa","year":"2015","journal-title":"J Clin Oncol"},{"key":"R17-28-20241021","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.jtho.2017.07.005","article-title":"ASCEND-8: A randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with Anaplastic Lymphoma Kinase (ALK)-rearranged metastatic Non-Small Cell Lung Cancer (NSCLC)","volume":"12","author":"Cho","year":"2017","journal-title":"J Thorac Oncol"},{"key":"R18-28-20241021","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jtho.2019.03.002","article-title":"Efficacy and safety of ceritinib (450 mg\/d or 600 mg\/d) with food versus 750-mg\/d fasted in patients with ALK receptor tyrosine kinase (ALK)-positive NSCLC: Primary efficacy results from the ASCEND-8 Study","volume":"14","author":"Cho","year":"2019","journal-title":"J Thorac Oncol"},{"key":"R19-28-20241021","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.lungcan.2008.04.013","article-title":"Non-small cell lung cancer and silent brain metastasis. Survival and prognostic factors","volume":"63","author":"S\u00e1nchez de Cos","year":"2009","journal-title":"Lung Cancer"},{"key":"R20-28-20241021","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/JTO.0b013e3181913e0e","article-title":"Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers","volume":"4","author":"Onozato","year":"2009","journal-title":"J Thorac Oncol"},{"key":"R21-28-20241021","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/S1470-2045(17)30689-7","article-title":"Leptomeningeal metastases in non-small-cell lung cancer","volume":"19","author":"Cheng","year":"2018","journal-title":"Lancet Oncol"},{"key":"R22-28-20241021","first-page":"655","article-title":"[Safety and preliminary efficacy of ceritinib 450 mg with food in Chinese ALK-positive non-small cell lung cancer]","volume":"23","author":"Tian","year":"2020","journal-title":"Zhongguo Fei Ai Za Zhi"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1453_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:39:59Z","timestamp":1787067599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1453_21"}},"subtitle":["Efficacy analysis of ceritinib (450mg) in ALK-rearrangement non-small-cell lung cancer patients with brain metastases in China"],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_1453_21","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]}}}